Share on LinkedInShare on LinkedIn

ARTICLE · 18 JULY 2011

Intellectual Property Weekly Abstracts Alert – Week Of July 11, 2011

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

The main issue in this proceeding involved the definition of "patentee" as it pertains to the requirement to report to the Patented Medicines Prices Review Board (PMPRB).

CanadaIntellectual Property

Edited by Chantal Saunders and Beverley Moore

OTHER CASES OF INTEREST

PMPRB Requires Generic Company to Report

In the Matter of ratiopharm Inc.

Drugs: ratio-Omeprazole, ratio-Ketorolac, ratio-Brimonidine, ratio- Paroxetine, ratio-Cefuroxime, ratio-Lamotrigine, ratio-Acyclovir, ratio-Ramipril, ratio-Diltiazem, ratio-Simvastatin, ratio-Sertraline, ratio-Quetiapine, ratio-Fenofibrate and ratio-Tamsulosin

The main issue in this proceeding involved the definition of "patentee" as it pertains to the requirement to report to the Patented Medicines Prices Review Board (PMPRB). ratiopharm does not hold any patents. However, it is authorized to sell certain medicines in Canada by the holders of the patents. The Board held that ratiopharm must file Form I information with respect to twelve drugs at issue. Regarding two additional drugs, the Board ordered ratiopharm to produce further documentation.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from